Literature DB >> 20063132

Rituximab therapy for refractory immune thrombocytopenic purpura in elder patients.

Akira Hangaishi, Tsuyoshi Takahashi, Akiko Masuda, Sumitaka Okada, Koji Kandabashi, Mineo Kurokawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20063132     DOI： 10.1007/s12185-009-0486-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  5 in total

Review 1.  Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.

Authors:  Donald M Arnold; Francesco Dentali; Mark A Crowther; Ralph M Meyer; Richard J Cook; Christopher Sigouin; Graeme A Fraser; Wendy Lim; John G Kelton
Journal:  Ann Intern Med       Date:  2007-01-02       Impact factor: 25.391

2.  Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura.

Authors:  Carolyn M Bennett; Zora R Rogers; Daniel D Kinnamon; James B Bussel; Donald H Mahoney; Thomas C Abshire; Hadi Sawaf; Theodore B Moore; Mignon L Loh; Bertil E Glader; Maggie C McCarthy; Brigitta U Mueller; Thomas A Olson; Adonis N Lorenzana; William C Mentzer; George R Buchanan; Henry A Feldman; Ellis J Neufeld
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

Review 3.  Current options for the treatment of idiopathic thrombocytopenic purpura.

Authors:  Donald M Arnold; John G Kelton
Journal:  Semin Hematol       Date:  2007-10       Impact factor: 3.851

4.  Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up results.

Authors:  Marta Medeot; Francesco Zaja; Nicola Vianelli; Marta Battista; Michele Baccarani; Francesca Patriarca; Franca Soldano; Miriam Isola; Stefano De Luca; Renato Fanin
Journal:  Eur J Haematol       Date:  2008-05-27       Impact factor: 2.997

5.  Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.

Authors:  Francisco Javier Peñalver; Victor Jiménez-Yuste; Manuel Almagro; Alberto Alvarez-Larrán; Lluis Rodríguez; Marisol Casado; Laura Gallur; Pilar Giraldo; Roberto Hernández; Dolores Menor; Maria José Rodríguez; Dolores Caballero; Raúl González; José Mayans; Isabel Millán; José Rafael Cabrera
Journal:  Ann Hematol       Date:  2006-03-21       Impact factor: 3.673
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.